IL-32 and premature aging in people living with HIV
Official title: Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.
Funded at Centre Hospitalier de L'universite de Montreal (University of Montreal Hospital) · NIH-11094103 · Data updated 2026-11-12
This work explores whether a blood protein called IL‑32 is linked to early aging problems like heart disease, weak bones, and frailty in people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre Hospitalier de L'universite de Montreal (University of Montreal Hospital) NIH-funded |
| Lab location | 1 site (Montreal, Canada) |
| Project start | September 30, 2016 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $829,283 |
| NIH project number | 4R01AG054324-09 |
| Project ID | NIH-11094103 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults living with HIV, especially those experiencing or at risk for cardiovascular disease, low bone density, changes in body composition, or frailty, would be the ideal candidates.
✕Less likely to help
People without HIV or those without concerns about aging-related conditions like heart disease, low bone density, or frailty are unlikely to benefit directly from this research.
What this research studies
If you have HIV, researchers will combine heart imaging, blood tests, and lab experiments to look at levels and effects of the inflammatory protein IL‑32. They will measure IL‑32 from people who have information on frailty, body composition, and bone density, and link those measures to cardiovascular imaging findings. Lab studies will test how IL‑32 might affect cells and bone or blood-vessel processes that relate to aging. Results aim to clarify whether IL‑32 could help identify who is at higher risk for age-related complications and point to possible ways to lower that risk.
Why it matters
Potential benefit: If successful, the work could help identify a blood marker that flags higher risk for early aging problems in people with HIV and suggest new targets to reduce that risk.
How similar studies have gone: Previous studies have suggested links between IL‑32 and inflammation, heart disease, and aging in HIV, but using IL‑32 as a marker or target across multiple aging traits is still relatively new.
Where this research is happening
-
Centre Hospitalier de L'universite de Montreal (University of Montreal Hospital)
Montreal, Canada Active
Researchers
- Principal investigator: Tremblay, Cecile — Centre Hospitalier de L'universite de Montreal (University of Montreal Hospital)
- Study coordinator: Tremblay, Cecile
Related research
Other NIH-funded projects on the same topics.
-
Understanding how HIV infection causes T cell aging.
This study is looking at how HIV makes certain immune cells age faster than they should, which can affect your health, and it aims to find ways to help improve the immune system for people living with HIV.
-
Understanding how HIV affects T cell aging and mitochondrial function
This study is looking at how HIV affects the aging of certain immune cells called T cells, especially how it impacts their energy production, and it's for people living with controlled HIV who want to understand more about their health and potential new treatments.
-
How life circumstances affect brain aging in people with end-stage kidney disease
This project looks at how neighborhood, income, education, and personal resilience relate to earlier memory and thinking problems in adults with end-stage kidney disease.
-
Mitigating HIV-Associated Premature Aging with Cannabinoids
A doctor-scientist team is testing whether cannabis-based anti-inflammatory effects can slow aging-related brain changes in people living with HIV.
-
Cannabis and aging-related brain changes in people living with HIV
This study looks at brain tissue after death to understand how cannabis use may affect Alzheimer’s-related brain changes in people living with HIV as they age.
-
Targeting aging pathways to help people living with HIV live longer, healthier lives
A patient-centered research project aims to slow aging-related health problems in people with HIV by studying how aging mechanisms work and testing strategies to slow inflammation and aging.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.